Literature DB >> 29559236

Mesenchymal chondrosarcomas showing immunohistochemical evidence of rhabdomyoblastic differentiation: a potential diagnostic pitfall.

Andrew L Folpe1, Rondell P Graham1, Anthony Martinez1, David Schembri-Wismayer1, Jennifer Boland1, Karen J Fritchie2.   

Abstract

The diagnosis of mesenchymal chondrosarcoma, a distinctive biphasic malignant neoplasm harboring the HEY1-NCOA2 gene fusion and consisting of primitive round to spindled cells admixed with foci of relatively mature hyaline cartilage, is usually straightforward by morphologic evaluation alone. However, in the setting of a limited biopsy, specimens lacking cartilage generate a broad differential diagnosis, encompassing a variety of other primitive sarcomas, including spindle cell/sclerosing rhabdomyosarcoma. Although a small number of cases of mesenchymal chondrosarcoma with aberrant skeletal muscle marker expression have been reported, pathologists are largely unaware of this potential diagnostic pitfall. We report 6 additional cases of mesenchymal chondrosarcoma showing expression of multiple skeletal muscle markers, including one case initially misdiagnosed as "spindle cell/sclerosing rhabdomyosarcoma" on needle biopsy. Awareness of this phenomenon and judicious application of molecular diagnostic testing for the HEY1-NCOA2 fusion are critical to avoid misclassification of mesenchymal chondrosarcoma as rhabdomyosarcoma, with potentially adverse patient impact.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Desmin; Mesenchymal chondrosarcoma; MyoD1; Myogenin; Rhabdomyosarcoma

Mesh:

Substances:

Year:  2018        PMID: 29559236     DOI: 10.1016/j.humpath.2018.03.012

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

Review 1.  What is new about the molecular genetics in matrix-producing soft tissue tumors? -The contributions to pathogenetic understanding and diagnostic classification.

Authors:  Yu-Chien Kao; Jen-Chieh Lee; Hsuan-Ying Huang
Journal:  Virchows Arch       Date:  2019-11-07       Impact factor: 4.064

Review 2.  The current landscape of rhabdomyosarcomas: an update.

Authors:  Julia Leiner; François Le Loarer
Journal:  Virchows Arch       Date:  2019-11-06       Impact factor: 4.064

3.  Expanding the Spectrum of Intraosseous Rhabdomyosarcoma: Correlation Between 2 Distinct Gene Fusions and Phenotype.

Authors:  Narasimhan P Agaram; Lei Zhang; Yun-Shao Sung; Marcela S Cavalcanti; Dianne Torrence; Leonard Wexler; Glenn Francis; Scott Sommerville; David Swanson; Brendan C Dickson; Albert J H Suurmeijer; Richard Williamson; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2019-05       Impact factor: 6.394

4.  Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma.

Authors:  Polona Safaric Tepes; Raffaella Sordella; Danilo Segovia; Sania Jevtic; Daniel Ramirez; Scott K Lyons
Journal:  Lab Invest       Date:  2021-11-26       Impact factor: 5.502

5.  S-100 Immunohistochemical Positivity in Rhabdomyoma: An Underestimated Potential Diagnostic Pitfall in Routine Practice.

Authors:  Andrea Palicelli; Antonio Ramponi; Guido Valente; Renzo Boldorini; Annalisa Balbo Mussetto; Magda Zanelli
Journal:  Diagnostics (Basel)       Date:  2022-04-02

6.  Intracranial Mesenchymal Chondrosarcoma Lacking the Typical Histopathological Features Diagnosed by HEY1-NCOA2 Gene Fusion.

Authors:  Atsuhito Uneda; Kazuhiko Kurozumi; Atsushi Fujimura; Atsunori Kamiya; Takanori Hirose; Hiroyuki Yanai; Isao Date
Journal:  NMC Case Rep J       Date:  2020-03-24

7.  Genomic profiling identifies genes and pathways dysregulated by HEY1-NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis.

Authors:  Wenqing Qi; Wojciech Rosikiewicz; Zhaohong Yin; Beisi Xu; Huihong Jiang; Shibiao Wan; Yiping Fan; Gang Wu; Lu Wang
Journal:  J Pathol       Date:  2022-04-26       Impact factor: 9.883

Review 8.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

9.  Primary mesenchymal chondrosarcoma of the kidney without HEY1-NCOA2 and IRF2BP2-CDX1 fusion: A case report and review.

Authors:  Atsushi Yamagishi; Osamu Ichiyanagi; Sei Naito; Hiromi Ito; Takanobu Kabasawa; Mitsunori Yamakawa; Norihiko Tsuchiya
Journal:  Oncol Lett       Date:  2019-11-22       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.